


### **Burundi**

# **Region: Central Africa**

### Key information on co-financing

- Gross National Income per capita (2017):
- Co-financing status (2019): Initial self-financing
- Country is projected to remain in initial self-financing phase for next 5 years



### **Immunisation financing**

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
<ul> <li>Government expenditure</li> </ul>	\$ 451,862	\$ 657,548	\$ 685,638	\$ 510,053	\$ 1,003,776
<ul> <li>Total expenditure</li> </ul>	\$ 9,773,702	\$ 9,072,982	\$ 10,977,119	\$ 9,598,500	\$ 8,750,104
- Government as % of total	5%	7%	6%	5%	11%
Routine immunisation					
<ul> <li>Government expenditure</li> </ul>	\$ 575,041	\$ 796,850	\$ 691,364	\$ 597,351	\$ 1,208,865
<ul> <li>Total expenditure</li> </ul>	\$ 10,959,737	\$ 9,510,868	\$ 11,689,423	\$ 9,766,531	\$ 11,032,802
<ul> <li>Government as % of total</li> </ul>	5%	8%	6%	6%	11%


Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product:

0.5%

Source: WHO National Health Accounts, 2015

# Expenditure on routine immunisation in 2017



#### **Gavi supported vaccines**

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Tetra DTP - Hib	Routine	2004	No
HepB	Routine	2004	No
Pentavalent	Routine	2005 - present	Yes
PCV	Routine	2011 - present	Yes
Measles	Routine	2012 - present	No
Rotavirus	Routine	2013 - present	Yes
IPV	Routine	2015 - present	No
HPV	Demonstration	2016 introduction	No
MenA	Campaign	2018	No


### **Co-financing payments**

		l amount paid by the country	Co-final	nced vaccines			
2008	\$	135,000	Penta	-	-		
2009	\$	174,000	Penta	-	-		
2010	\$	169,000	Penta	-	-		
2011	\$	264,000	Penta	-	PCV		
2012	\$	463,000	Penta	-	PCV		
2013	\$	451,000	Penta	Rota	PCV		
2014	\$	649,000	Penta	Rota	PCV		
2015	\$	676,000	Penta	Rota	PCV		
2016	\$	511,000	Penta	Rota	PCV		
2017	\$	495,000	Penta	Rota	PCV		
2018	\$	717,000	Penta	Rota	PCV		

## **Co-financing obligations for 2019**

	Co-finar (in US\$)	ncing obligations	Co-financing obligations (in doses)	
Pentavalent	\$	252,000		354,500
PCV	\$	254,500		85,200
Rota	\$	161,500		70,500
Total	\$	668,000		

## Co-financing projections for 2020 - 2024



	2020		2021			2022	2023	2024	
Penta	\$	209,371	\$	216,922	\$	222,806	\$ 228,663	\$	234,580
PCV	\$	196,950	\$	204,054	\$	209,589	\$ 215,098	\$	220,665
Rotavirus	\$	125,232	\$	129,731	\$	133,234	\$ 136,722	\$	140,245
Total	\$	531,553	\$	550,707	\$	565,629	\$ 580,483	\$	595,490

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
  Final co-financing obligations will be communicated through decision letters.